Technology’s Role In Advancing Outcomes & Reducing The Cost Of Care For The SMI Population is starting in

Early Changes In Waivered Clinicians & Utilization of Buprenorphine For Opioid Use Disorder After Implementation Of The 2021 HHS Buprenorphine Practice Guideline

On December 2, 2022, the U.S. Department of Health and Human Services (HHS) published this report on early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS buprenorphine practice guidelines. This brief addresses both of these research questions by examining changes in clinician waiver uptake and the number of patients receiving buprenorphine from pharmacies for OUD treatment in the early months after the Practice Guidelines took effect (i.e., between June 2021 and December 2021 . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.